Fundraising Fox

Olatec Therapeutics

New York, US · 2 known investors

Olatec develops a pharmaceutical platform targeting acute and chronic inflammatory diseases, with its lead compound dapansutrile (OLT1177), a NLRP3 inhibitor currently in Phase 2 clinical trials in the US and Europe.

BiotechHealthtechMedical Devices

Founders & leadership

DS
Damaris SkourasinFounder & CEO

Investors · 2

Advection Growth CapitalNew York City

Also in the syndicate · 1

Sanders Morris Harrislead

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeries AFeb 2023

    Sanders Morris Harris (lead)

    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Olatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson's Studies - BioSpacebiospace.com · Jan 2026Olatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson's Studiesprnewswire.com · Jan 2026Olatec gets $40M to put anti-inflammatory in late-stage trial; Enliven goes public, raises $165Mendpoints.news · Feb 2023Olatec Therapeutics Announces the Final Closing, Led by Sanders Morris Harris, on Its $40 Million Series A Financing Roundbusinesswire.com · Feb 2023

Frequently asked questions

What does Olatec Therapeutics do?
Olatec develops a pharmaceutical platform targeting acute and chronic inflammatory diseases, with its lead compound dapansutrile (OLT1177), a NLRP3 inhibitor currently in Phase 2 clinical trials in the US and Europe.
Who founded Olatec Therapeutics?
Olatec Therapeutics was founded by Damaris Skouras.
Who are Olatec Therapeutics's investors?
Olatec Therapeutics's investors include Advection Growth Capital.
Where is Olatec Therapeutics headquartered?
Olatec Therapeutics is headquartered in New York, US.